Rheumatology.net

Rheumatology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Rheumatoid arthritis ( RA ), along with glucocorticoid use, is associated with cardiovascular disease. Cardiovascular safety of glucocorticoids in rheumatoid arthritis is controversial and may be re ...


Pain is a core domain of psoriatic arthritis ( PsA ). A post hoc analysis has evaluated time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic ar ...


The objective of the study was to report efficacy and safety of Upadacitinib ( Rinvoq ) through 1 year in patients with ankylosing spondylitis ( AS ). In the SELECT-AXIS 1 study, adults with active ...


The co-primary endpoint results from a recently completed post-marketing required safety study, ORAL Surveillance were presented. The primary objective of this study was to evaluate the safety of To ...


New phase 3 data from the SELECT-CHOICE clinical trial have shown that Upadacitinib ( Rinvoq ), 15 mg, once daily, met the primary endpoint of non-inferiority versus Abatacept ( Orencia ) on change fr ...


An update of the European League Against Rheumatism ( EULAR ) rheumatoid arthritis management recommendations to account for the most recent developments in the field, was released. An internationa ...


Filgotinib is JAK-1 selective catalytic inhibitor. Due to its target selectivity, Filgotinib is estimated to have a good efficacy and a better safety profile than unselective JAK inhibitors ( JAKi ). ...


Upadacitinib ( Rinvoq ) was developed as a JAK1-selective inhibitor by exploiting differences in the non-conserved domains outside the active sites of JAK1 and JAK2. In cellular assays, Upadacitinib ...


The SELECT‐EARLY trial studied the effect of Upadacitinib ( Rinvoq ), an oral, reversible, JAK inhibitor, as monotherapy in patients with predominantly early rheumatoid arthritis who are naïve or have ...


In phase 3 trials, Upadacitinib ( Rinvoq ), an oral JAK1-selective inhibitor, has been assessed as monotherapy versus Methotrexate ( SELECT-EARLY ) and in combination with Methotrexate versus Adalimum ...


Anifrolumab, a human monoclonal antibody to the type I IFN receptor subunit 1, had robust efficacy in a phase 2 study in patients with active systemic lupus erythematosus ( SLE ). The first phase 3 ...


Sodium glucose co-transporter 2 ( SGLT2 ) inhibitors reduce serum urate levels. In a post hoc analysis researchers have investigated the effect of Canagliflozin ( Invokana ) compared to placebo on gou ...


Allopurinol is commonly prescribed for gout, and its clinical use may expand with ongoing trials assessing its potential cardiorenal benefits. Because heart disease has been suggested to be a risk f ...


Objective of the study was to disentangle the role of nonsteroidal anti-inflammatory drugs ( NSAIDs ) in the increased risk of cardiovascular disease ( CVD ) among osteoarthritis patients. This lon ...


A study has compared efficacy and safety of subcutaneous Sarilumab ( Kevzara ) 200 mg and 150 mg every 2 weeks plus conventional synthetic disease-modifying antirheumatic drugs ( +csDMARDs ) versus o ...